Apogee Therapeutics stock initiated with Buy rating at Craig-Hallum
PositiveFinancial Markets

Apogee Therapeutics has received a Buy rating from Craig-Hallum, signaling strong confidence in the company's future performance. This endorsement is significant as it may attract more investors and boost the stock's value, reflecting optimism about Apogee's growth potential in the biotech sector.
— Curated by the World Pulse Now AI Editorial System






